| Business Summary | | KeraVision,
Inc.
developed
a
new
category
of
non-laser
vision
correction
products
for
the
treatment
of
common
vision
disorders,
including
myopia
(nearsightedness),
hyperopia
(farsightedness)
and
astigmatism,
to
offer
an
alternative
to
eyeglasses,
contact
lenses
and
other
vision
correction
surgical
procedures.
Its
first
product,
Intacs
corneal
ring
segments,
based
on
the
Company's
proprietary
patented
technology,
has
been
approved
by
the
Food
and
Drug
Administration
for
correcting
mild
myopia.
Intacs
are
designed
to
permanently
correct
a
patient's
vision
while
providing
the
option
of
removability.
The
placement
of
Intacs
is
a
simple,
minimally
invasive
procedure
that
can
be
performed
on
an
outpatient
basis
typically
in
15
minutes
or
less.
In
March
2001,
the
Company
filed
for
protection
pursuant
to
Chapter
11
of
the
United
States
Bankruptcy
Code. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | KeraVision,
Inc.
was
founded
to
develop
and
commercialize
proprietary
medical
products
for
the
treatment
of
common
vision
problems,
including
myopia,
hyperopia
and
astigmatism.
For
the
fiscal
year
ended
12/31/00,
net
sales
fell
77%
to
$2.4
million.
Net
loss
applicable
to
Common
rose
38%
to
$39.8
million.
Results
reflect
lower
sales
of
training-related
surgeon
kits
due
to
the
reduction
in
new
surgeon
training,
partially
offset
by
lower
research
and
development
expenses. | More
from
Market Guide: Significant
Developments |
| Officers | | | FY1999 Pay | |
| Steven Henderson, 40 VP
of Sales | -- | David Heniges, 56 VP
- Europe | $193K | Richard Meader, 54 VP
- Quality Assurance | -- | Michael Taylor, 49 VP,
Corp. Relations | -- | Robert Wood, 41 VP,
Manufacturing | -- | Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|